Learn More
PURPOSE This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573; MK-8669), a nonprodrug rapamycin(More)
3050 Background: EGFR is over-expressed in >80% of renal neoplasms and is implicated in tumor initiation and progression. Antitumor activity against RCC in the phase I study of OSI-774, a selective(More)
3076 Background: AP23573, a non-prodrug rapamycin analog, potently inhibits mTOR, a downstream effector of the PI3K/Akt and nutrient signaling pathways. AP23573 demonstrated potent inhibition of(More)
  • 1